• Lee Schalop, MD, COO of Oncoceutics to present ONC201 and our clinical trials in glioma patients with the H3 K27M mutation at the BioNJ BioPartnering Conference in Somerset, NJ on May 3, 2018. His presentation will further talk about relevant background information for H3 K27M-mutant brain tumors, including DIPG and other midline gliomas, and discuss development and commercialization strategies for ONC201, ONC206 and ONC212.

    BioNJ’s Eighth Annual BioPartnering Conferenc

    The conference, developed in partnership with J.P. Morgan, will bring together nearly 400 public and private company investors, life sciences professionals and academic partners from the Northeast to Mid-Atlantic states.

    Please click here for more information about the conference. You can find the full agenda here.